We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

59 hedge funds and large institutions have $260M invested in Aspire Biopharma in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

13% more funds holding

Funds holding: 52 → 59 (+7)

8% more capital invested

Capital invested by funds: $241M → $260M (+$18.9M)

0% more ownership

Funds ownership: 0.07% → 0.07% (+0%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
7
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$8.73M
2
Goldman Sachs
Goldman Sachs
New York
+$4.55M
3
MF
Magnetar Financial
Illinois
+$4M
4
SCM
Shaolin Capital Management
Florida
+$2.51M
5
PC
Periscope Capital
Ontario, Canada
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$4.56M
2
WAM
Wolverine Asset Management
Illinois
-$3.67M
3
HI
HBK Investments
Texas
-$2.99M
4
CCM
Context Capital Management
California
-$2.52M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$2.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIA
51
Schechter Investment Advisors
Michigan
$266K -$36.2K -3 -12%
WC
52
Wealthspring Capital
New York
$266K -$36.2K -3 -12%
PI
53
PEAK6 Investments
Illinois
$254K – – –
BI
54
Bulldog Investors
New Jersey
$254K +$253K +21 New
COPPSERS
55
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$254K +$253K +21 New
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$208K -$12.1K -1 -6%
CCA
57
Castle Creek Arbitrage
Colorado
$203K +$205K +17 New
CAPTRUST Financial Advisors
58
CAPTRUST Financial Advisors
North Carolina
$121K +$121K +10 New
TRCT
59
Tower Research Capital (TRC)
New York
$2K – – –
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$1.27K -$96.6K -8 -7%
HI
61
HBK Investments
Texas
– -$2.99M -250 Closed
GT
62
Glenmede Trust
Pennsylvania
– -$985K -82 Closed
ECU
63
Eisler Capital (UK)
United Kingdom
– -$499K -42 Closed
OMC
64
Old Mission Capital
Illinois
– -$166K -14 Closed
1 2
3

ASBP Hedge Fund Activity: Q3 2022 in Review

59 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2022, worth a combined $260M — up 7.8% from $241M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ASBP positions and 4 closed out — a net gain of 7 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $8.73M. The largest seller was AQR Arbitrage, cutting an estimated $4.56M.

  • 59 institutional investors held Aspire Biopharma (ASBP) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $260M of Aspire Biopharma stock for Q3 2022, up 7.8% quarter-over-quarter.
  • 11 funds opened new Aspire Biopharma positions in Q3 2022 and 4 closed out, a net change of +7 holders.
  • The largest Aspire Biopharma buyer in Q3 2022 was Highbridge Capital Management, an estimated $8.73M added.
  • The largest Aspire Biopharma seller in Q3 2022 was AQR Arbitrage, an estimated $4.56M sold.

Based on aggregated 13F filings for Q3 2022.